semicarbazide-sensitive amine oxidase (ssao)

BI-1467335 HCl(BI 1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO) that helps improve chronic obstructive pulmonary disease in mice[2].

PXS-4681A is a powerful, specific, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO; VAP-1), with an oral activity and a Ki value of 37 nM. It exhibits exceptional selectivity towards related amine oxidases, ion channels, and seven-transmembrane domain receptors. Additionally, PXS-4681A demonstrates potent anti-inflammatory properties.

SSAO inhibitor-1 is a compound that acts as an inhibitor of semicarbazide-sensitive amine oxidase (SSAO). It exhibits anti-inflammatory properties and is commonly employed in research pertaining to liver diseases.

SSAO inhibitor-2 (Compound 1) is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC50 values <10 nM for human SSAO and 10-100 μM for MAO-A, respectively [1]. It can be used in the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and multiple sclerosis.

SSAO inhibitor-3 (Compound 2) is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC50 values of 0.1-10 μM and <10 nM for human AOC1 and SSAO, respectively, and can be used in the study of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and multiple sclerosis, etc. [1].

MD 220661 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and a substrate of the enzyme.